191 related articles for article (PubMed ID: 27469075)
1. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
[TBL] [Abstract][Full Text] [Related]
2. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Landsburg DJ; Koike A; Nasta SD; Svoboda J; Schuster SJ; Wasik MA; Caponetti GC
Cancer Immunol Immunother; 2021 Mar; 70(3):869-874. PubMed ID: 32857184
[TBL] [Abstract][Full Text] [Related]
3. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
[TBL] [Abstract][Full Text] [Related]
4. A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Kang JH; Kim HR; Lee GW
Oncotarget; 2017 Jul; 8(29):47007-47019. PubMed ID: 28388585
[TBL] [Abstract][Full Text] [Related]
5. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
Nowakowski GS; Blum KA; Kahl BS; Friedberg JW; Baizer L; Little RF; Maloney DG; Sehn LH; Williams ME; Wilson WH; Leonard JP; Smith SM
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27986884
[TBL] [Abstract][Full Text] [Related]
6. ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
Nowakowski GS; Zhu J; Zhang Q; Brody J; Sun X; Maly J; Song Y; Rizvi S; Song Y; Lansigan F; Jing H; Cao J; Lue JK; Luo W; Zhang L; Li L; Han I; Sun J; Jivani M; Liu Y; Heineman T; Smith SD
Future Oncol; 2020 May; 16(15):991-999. PubMed ID: 32250167
[TBL] [Abstract][Full Text] [Related]
7. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
Spina M; Balzarotti M; Uziel L; Ferreri AJ; Fratino L; Magagnoli M; Talamini R; Giacalone A; Ravaioli E; Chimienti E; Berretta M; Lleshi A; Santoro A; Tirelli U
Oncologist; 2012; 17(6):838-46. PubMed ID: 22610154
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma: A STROBE-compliant article.
Zhang Y; Wei Z; Li J; Gao R; Liu P
Medicine (Baltimore); 2018 Jul; 97(30):e11719. PubMed ID: 30045337
[TBL] [Abstract][Full Text] [Related]
9. Targeting the intratumor heterogeneity in PMBL.
Ritz O; Möller P; Ushmorov A
Cell Cycle; 2014; 13(15):2317-8. PubMed ID: 25483178
[No Abstract] [Full Text] [Related]
10. Lung intravascular large B-cell lymphoma with ground glass opacities on chest computed tomography: a case report.
Xiao D; Fu C; Long X; Liu W; Chen C; Zhou J; Fan S
Int J Clin Exp Pathol; 2014; 7(8):5285-90. PubMed ID: 25197411
[TBL] [Abstract][Full Text] [Related]
11. High-grade B-cell lymphoma, not otherwise specified, presenting as primary peritoneal lymphomatosis and successfully treated with dose-adjusted EPOCH-R.
Fujimi A; Nagamachi Y; Yamauchi N; Onoyama N; Hayasaka N; Matsuno T; Koike K; Goto Y; Ihara K; Kato J; Nishisato T; Kawase H; Yano T; Kanaseki T; Sugita S; Kobune M
J Clin Exp Hematop; 2024 Mar; 64(1):37-44. PubMed ID: 38281744
[TBL] [Abstract][Full Text] [Related]
12. Synchronous colonic B cell lymphoma and adenocarcinoma in an elderly patient treated with R-mini-CHOP followed by resection.
Schep D; Van Koughnett JA; Velker V; Correa RJM
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35508353
[TBL] [Abstract][Full Text] [Related]
13. Fuzzy neural network applied to gene expression profiling for predicting the prognosis of diffuse large B-cell lymphoma.
Ando T; Suguro M; Hanai T; Kobayashi T; Honda H; Seto M
Jpn J Cancer Res; 2002 Nov; 93(11):1207-12. PubMed ID: 12460461
[TBL] [Abstract][Full Text] [Related]
14. Molecular and cytogenetic evidence of high-grade B-cell lymphoma with CCND1 rearrangement as a secondary event.
Yap FHX; Amanuel B; Rijhumal H; Martin AM; Allanson B
Pathology; 2024 Jun; 56(4):585-588. PubMed ID: 38097450
[No Abstract] [Full Text] [Related]
15. Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma.
Haws BT; Cui W; Persons DL; Zhang D
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):679-683. PubMed ID: 27633159
[TBL] [Abstract][Full Text] [Related]
16. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.
Nguyen L; Papenhausen P; Shao H
Genes (Basel); 2017 Apr; 8(4):. PubMed ID: 28379189
[TBL] [Abstract][Full Text] [Related]
17. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
18. Genetic profiling of
Ennishi D; Mottok A; Ben-Neriah S; Shulha HP; Farinha P; Chan FC; Meissner B; Boyle M; Hother C; Kridel R; Lai D; Saberi S; Bashashati A; Shah SP; Morin RD; Marra MA; Savage KJ; Sehn LH; Steidl C; Connors JM; Gascoyne RD; Scott DW
Blood; 2017 May; 129(20):2760-2770. PubMed ID: 28351934
[TBL] [Abstract][Full Text] [Related]
19. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
Sesques P; Johnson NA
Blood; 2017 Jan; 129(3):280-288. PubMed ID: 27821509
[TBL] [Abstract][Full Text] [Related]
20. Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer.
Spolverato G; Bagante F; Ethun CG; Poultsides G; Tran T; Idrees K; Isom CA; Fields RC; Krasnick B; Winslow E; Cho C; Martin RC; Scoggins CR; Shen P; Mogal HD; Schmidt C; Beal E; Hatzaras I; Shenoy R; Maithel SK; Pawlik TM
World J Surg; 2017 Jan; 41(1):224-231. PubMed ID: 27549595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
